Prescription drug · ANDA
Benztropine Mesylate NDC 70752-125
Benztropine mesylate 2 mg/1 · Tablet · Oral · QUAGEN PHARMACEUTICALS LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70752-125-10 | 70752012510 | 100 TABLET in 1 BOTTLE, PLASTIC (70752-125-10)Marketed from Aug 11, 2025 | |
| 70752-125-11 | 70752012511 | 1000 TABLET in 1 BOTTLE, PLASTIC (70752-125-11)Marketed from Aug 11, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Benztropine Mesylate
- Generic name (nonproprietary)
- benztropine mesylate
- Active ingredients
- Benztropine mesylate — 2 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- QUAGEN PHARMACEUTICALS LLC
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 212694
- Marketing start
- Listing expires
- Other FDA classes
- Cholinergic Antagonists (Mechanism)Histamine Receptor Antagonists (Mechanism)
- Identifiers
- Product ID 70752-125_073409b4-0ae6-43d5-804a-a15ca581ecd9SPL ID 073409b4-0ae6-43d5-804a-a15ca581ecd9SPL set ID e1f0a249-e660-4592-9ffc-1c02b1022778RxCUI 885209, 885213, 885219UNII WMJ8TL7510
- Pharmacologic class
- Anticholinergic; Antihistamine
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N470752012510followed by a unit qualifier and the quantityPackage 70752-0125-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Benztropine mesylate tablets are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders [except tardive dyskinesia - see PRECAUTIONS ] due to neuroleptic drugs (e.g., phenothiazines).
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 212694
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Benztropine Mesylate | Benztropine mesylate 1 mg/1 | TabletOral | Bryant Ranch Prepack | 72162-2595 |
| Benztropine Mesylate | Benztropine mesylate .5 mg/1 | TabletOral | Bryant Ranch Prepack | 72162-2594 |
| Benztropine Mesylate | Benztropine mesylate 2 mg/1 | TabletOral | Bryant Ranch Prepack | 72162-2596 |
| Benztropine Mesylate | Benztropine mesylate 1 mg/1 | TabletOral | QUAGEN PHARMACEUTICALS LLC | 70752-124 |
| Benztropine Mesylate | Benztropine mesylate .5 mg/1 | TabletOral | QUAGEN PHARMACEUTICALS LLC | 70752-123 |